Literature DB >> 20852320

The psychosocial effects of adult strabismus: a review.

Jonathan M Durnian1, Carmel P Noonan, Ian B Marsh.   

Abstract

Correction of adult strabismus is not a cosmetic procedure but one that restores normality to an individual's appearance that has been altered by a disease process. Two fundamental principles underpinning facial attractiveness are symmetry and averageness-manifest strabismus affects both of these giving an unconscious signal of poor genetic history. The presence of manifest strabismus adversely affects many aspects of patients' lives including finding a partner, job prospects and interaction with peers, and may manifest more seriously as psychiatric disorders. Surgical correction has been shown to be safe and effective for the functional problems of strabismus in adults but the hugely positive effects on the psychosocial aspects are only now becoming apparent. The advent of a new adult strabismus specific quality-of-life questionnaire and its subsequent validation will make this quantification of improvement easier. The wider medical community and the public at large should be made aware of the benefits of corrective strabismus surgery in adults.

Entities:  

Mesh:

Year:  2010        PMID: 20852320     DOI: 10.1136/bjo.2010.188425

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Surgical correction of childhood intermittent exotropia and the risk of developing mental illness.

Authors:  Khin P Kilgore; Román A Barraza; David O Hodge; Jeff A McKenzie; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2014-06-19       Impact factor: 5.258

2.  Awareness, perceptions and knowledge of strabismus among patients visiting a tertiary eye clinic in Southwest Nigeria.

Authors:  Michaeline A Isawumi; Mildred Ulaikere; Olubusayo O Adejumo; Modupe Adebayo; Ramesh Kekunnaya
Journal:  Int Ophthalmol       Date:  2014-01-20       Impact factor: 2.031

3.  The psychological well-being and appearance concerns of patients presenting with ptosis.

Authors:  H S Richards; E Jenkinson; N Rumsey; P White; H Garrott; H Herbert; F Kalapesi; R A Harrad
Journal:  Eye (Lond)       Date:  2013-12-20       Impact factor: 3.775

4.  Health-Related Quality of Life (HRQoL) in Young Adults with Strabismus in India.

Authors:  Surendra P Sah; Indra P Sharma; Monica Chaudhry; Mousumi Saikia
Journal:  J Clin Diagn Res       Date:  2017-02-01

5.  Appearance concerns in ophthalmic patients.

Authors:  H James; E Jenkinson; R Harrad; D G Ezra; S Newman
Journal:  Eye (Lond)       Date:  2011-05-20       Impact factor: 3.775

6.  Quality of life in adults with strabismus.

Authors:  Melinda Y Chang; Federico G Velez; Joseph L Demer; Sherwin J Isenberg; Anne L Coleman; Stacy L Pineles
Journal:  Am J Ophthalmol       Date:  2014-12-09       Impact factor: 5.258

7.  Improvement in patients' quality-of-life following strabismus surgery: evaluation of postoperative outcomes using the Adult Strabismus 20 (AS-20) score.

Authors:  P Glasman; R Cheeseman; V Wong; J Young; J M Durnian
Journal:  Eye (Lond)       Date:  2013-08-09       Impact factor: 3.775

Review 8.  Psychosocial interventions for improving quality of life outcomes in adults undergoing strabismus surgery.

Authors:  Kelly MacKenzie; Joanne Hancox; Hayley McBain; Daniel G Ezra; Gill Adams; Stanton Newman
Journal:  Cochrane Database Syst Rev       Date:  2016-05-12

9.  Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial.

Authors:  Assaf Gershoni; Alon Tiosano; Meydan Ben Ishai; Edward Barayev; Guy J Ben Simon; Iftach Yassur
Journal:  Eye (Lond)       Date:  2021-03-10       Impact factor: 3.775

10.  Surgery versus Active Monitoring in Intermittent Exotropia (SamExo): study protocol for a pilot randomised controlled trial.

Authors:  Deborah Buck; Elaine McColl; Christine J Powell; Jing Shen; John Sloper; Nick Steen; Robert Taylor; Peter Tiffin; Luke Vale; Michael P Clarke
Journal:  Trials       Date:  2012-10-16       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.